Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1970 1
1972 2
1973 4
1975 6
1976 5
1977 3
1978 2
1979 2
1980 3
1981 2
1982 1
1983 4
1984 5
1985 1
1986 1
1987 2
1988 5
1990 5
1991 1
1992 2
1993 3
1994 1
1995 2
1996 4
1999 5
2000 2
2001 3
2002 2
2003 2
2008 2
2010 2
2011 1
2012 1
2013 2
2014 1
2015 2
2017 1
2018 4
2019 3
2020 8
2021 5
2022 8
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Results by year

Filters applied: . Clear all
Page 1
Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium.
Buchmann S, Schrappe M, Baruchel A, Biondi A, Borowitz M, Campbell M, Cario G, Cazzaniga G, Escherich G, Harrison CJ, Heyman M, Hunger SP, Kiss C, Liu HC, Locatelli F, Loh ML, Manabe A, Mann G, Pieters R, Pui CH, Rives S, Schmiegelow K, Silverman LB, Stary J, Vora A, Brown P. Buchmann S, et al. Blood. 2022 Mar 24;139(12):1785-1793. doi: 10.1182/blood.2021012328. Blood. 2022. PMID: 34192312 Free PMC article.
Representatives of the major international ALL clinical trial groups convened to establish consensus definitions. ...Relapse can only be defined in patients who have achieved CR and must include a specific threshold of leukemic cells in the bone marrow confirmed by …
Representatives of the major international ALL clinical trial groups convened to establish consensus definitions. ...Relapse c …
Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL.
Qi Y, Zhao M, Hu Y, Wang Y, Li P, Cao J, Shi M, Tan J, Zhang M, Xiao X, Xia J, Ma S, Qiao J, Yan Z, Li H, Pan B, Sang W, Li D, Li Z, Zhou J, Huang H, Liang A, Zheng J, Xu K. Qi Y, et al. Blood. 2022 Jun 9;139(23):3376-3386. doi: 10.1182/blood.2021013733. Blood. 2022. PMID: 35338773 Free PMC article. Clinical Trial.
Few studies have described chimeric antigen receptor (CAR) T-cell therapy for patients with B-cell acute lymphoblastic leukemia (B-ALL) with central nervous system leukemia (CNSL) because of concerns regarding poor response and treatment-related neurot …
Few studies have described chimeric antigen receptor (CAR) T-cell therapy for patients with B-cell acute lymphoblastic leukemia (B-ALL) with …
Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Shen S, Chen X, Cai J, Yu J, Gao J, Hu S, Zhai X, Liang C, Ju X, Jiang H, Jin R, Wu X, Wang N, Tian X, Pan K, Jiang H, Sun L, Fang Y, Li CK, Hu Q, Yang M, Zhu Y, Zhang H, Li C, Pei D, Jeha S, Yang JJ, Cheng C, Tang J, Zhu X, Pui CH. Shen S, et al. JAMA Oncol. 2020 Mar 1;6(3):358-366. doi: 10.1001/jamaoncol.2019.5868. JAMA Oncol. 2020. PMID: 31944221 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: This open-label, phase 3 randomized clinical trial was conducted at 20 hospitals in China. Enrollment occurred from January 1, 2015, through September 18, 2018, and randomization was stopped on October 4, 2018, when t …
DESIGN, SETTING, AND PARTICIPANTS: This open-label, phase 3 randomized clinical trial was conducted at 20 hospitals in …
Central nervous system lymphoma.
Lister A, Abrey LE, Sandlund JT. Lister A, et al. Hematology Am Soc Hematol Educ Program. 2002:283-96. doi: 10.1182/asheducation-2002.1.283. Hematology Am Soc Hematol Educ Program. 2002. PMID: 12446428 Review.
In Section II, Dr. John Sandlund reviews the success of sequential clinical trials of overall therapy for acute lymphoblastic leukemia in childhood, identifying those patients at high risk of central nervous system leukemia and the development o …
In Section II, Dr. John Sandlund reviews the success of sequential clinical trials of overall therapy for acute lymphoblastic leukemi …
Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia.
McNeer JL, Schmiegelow K. McNeer JL, et al. Curr Hematol Malig Rep. 2022 Feb;17(1):1-14. doi: 10.1007/s11899-021-00640-6. Epub 2022 Jan 13. Curr Hematol Malig Rep. 2022. PMID: 35025035 Review.
In this review, we aim to identify areas of ongoing debate on this topic, review the biology of CNS leukemia, and summarize clinical trial data that address some of these questions. RECENT FINDINGS: Both retrospective and meta-analyses have demonstrated that few pat …
In this review, we aim to identify areas of ongoing debate on this topic, review the biology of CNS leukemia, and summarize clinical …
Prognostic factors for clinical outcomes of patients with central nervous system leukemia.
Bharucha J, Cao Q, Sachs Z, Smith A, Williams S, Amin K, Bachanova V, Warlick E, Brunstein C, Weisdorf D, Bejanyan N. Bharucha J, et al. Hematol Oncol Stem Cell Ther. 2021 Sep;14(3):240-245. doi: 10.1016/j.hemonc.2020.11.004. Epub 2020 Nov 24. Hematol Oncol Stem Cell Ther. 2021. PMID: 33271117 Free PMC article. Clinical Trial.
Prognostic factors associated with clinical outcomes of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients with central nervous system (CNS) involvement are unknown. ...
Prognostic factors associated with clinical outcomes of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients …
Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT.
He JB, Zhang X, Guo ZW, Liu MM, Xu N, Huang F, Fan ZP, Xuan L, Deng L, Lin SH, Xu J, Sun J, Liu QF. He JB, et al. Int J Cancer. 2020 Aug 15;147(4):1071-1077. doi: 10.1002/ijc.32817. Epub 2019 Dec 19. Int J Cancer. 2020. PMID: 31785158 Free article.
Central nervous system leukemia (CNSL) relapse is relatively common among Philadelphia chromosome-positive (Ph+) leukemia patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT). ...Our data from a small number of samples su …
Central nervous system leukemia (CNSL) relapse is relatively common among Philadelphia chromosome-positive (Ph+) …
High dose cytarabine: a review.
Bolwell BJ, Cassileth PA, Gale RP. Bolwell BJ, et al. Leukemia. 1988 May;2(5):253-60. Leukemia. 1988. PMID: 3287015 Review.
Because intravenous HDARAC achieves high levels in the spinal fluid, it is useful to treat central nervous system leukemia and may provide adequate CNS prophylaxis in acute lymphocytic leukemia. HDARAC is reported to be active in advanced non-Hodgkin l …
Because intravenous HDARAC achieves high levels in the spinal fluid, it is useful to treat central nervous system le …
Central nervous system leukemia.
Bleyer WA. Bleyer WA. Pediatr Clin North Am. 1988 Aug;35(4):789-814. doi: 10.1016/s0031-3955(16)36510-5. Pediatr Clin North Am. 1988. PMID: 3047654 Review.
The improved outcome in intellectual and academic performance in the NCI-191/CCG-134P conjoint trial of the CCSG and the Pediatric Branch described above (see section of Presymptomatic CNS Therapy) appears to confirm this observation. ...If CNS RT must be combined with MTX …
The improved outcome in intellectual and academic performance in the NCI-191/CCG-134P conjoint trial of the CCSG and the Pediatric Br …
118 results